Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials

Erin D. Michos, Christopher T. Sibley, Jefferson T. Baer, Michael J. Blaha, Roger S. Blumenthal

Research output: Contribution to journal › Review article › peer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials'. Together they form a unique fingerprint.

Medicine & Life Sciences